Open-House original discount contracts 2026-13 Etrasimod

Summary

The tender concerns the conclusion of discount contracts for the active substance Etrasimod with all suitable pharmaceutical companies. The procurement is conducted under the Open-House Originale procedure; no negotiations on contract contents take place; uniform terms apply. The participating health insurers do not grant exclusivity to any contract partner. The contract duration is up to 24 months, starting 1 November 2026. The contract ends no later than 31 October 2028, regardless of the date of contract conclusion. If patent expiry or market exclusivity ends earlier, the contract ends at the end of the expiry month. Joining this Open-House Originale procedure is possible at any time during the contract term. Further information is available in the participating and contract documents. The tender relates to supplies.